{"filing":{"accession_number":"0001785530-26-000018","cik":"0001785530","ticker":"HOWL","company_name":"Werewolf Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"howl-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/howl-20260731.htm"},"events":[{"id":22910,"run_id":20746,"accession_number":"0001785530-26-000018","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on July 31, 2026, disclosing financial results including collaboration revenue of $21.0 million, R\u0026D expenses of $6.2 million, G\u0026A expenses of $7.7 million, and net income of $3.7 million. The press release is furnished as Exhibit 99.1 and includes condensed consolidated statements of operations and balance sheet data, which are typical components of an earnings announcement. The disclosure is material as it reports quarterly financial performance and cash position ($22.0 million as of June 30, 2026).","company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":23008,"accession_number":"0001785530-26-000018","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on July 31, 2026, disclosing financial results including collaboration revenue of $21.0 million, R\u0026D expenses of $6.2 million, G\u0026A expenses of $7.7 million, and net income of $3.7 million. The press release is furnished as Exhibit 99.1 and includes condensed consolidated statements of operations and balance sheet data, which are typical components of an earnings announcement. The disclosure is material as it reports quarterly financial performance and cash position ($22.0 million as of June 30, 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:38:56.300243+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23008,"accession_number":"0001785530-26-000018","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on July 31, 2026, disclosing financial results including collaboration revenue of $21.0 million, R\u0026D expenses of $6.2 million, G\u0026A expenses of $7.7 million, and net income of $3.7 million. The press release is furnished as Exhibit 99.1 and includes condensed consolidated statements of operations and balance sheet data, which are typical components of an earnings announcement. The disclosure is material as it reports quarterly financial performance and cash position ($22.0 million as of June 30, 2026).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:38:56.300243+00:00","company_name":"Werewolf Therapeutics, Inc.","ticker":"HOWL","filing_date":"2026-07-31"}]}